196 related articles for article (PubMed ID: 24326130)
1. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines.
Phillip CJ; Zaman S; Shentu S; Balakrishnan K; Zhang J; Baladandayuthapani V; Taverna P; Redkar S; Wang M; Stellrecht CM; Gandhi V
J Hematol Oncol; 2013 Dec; 6():92. PubMed ID: 24326130
[TBL] [Abstract][Full Text] [Related]
2. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
[TBL] [Abstract][Full Text] [Related]
3. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M
Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459
[TBL] [Abstract][Full Text] [Related]
4. ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.
Lath DL; Buckle CH; Evans HR; Fisher M; Down JM; Lawson MA; Chantry AD
PLoS One; 2018; 13(6):e0199517. PubMed ID: 29924867
[TBL] [Abstract][Full Text] [Related]
5. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
[TBL] [Abstract][Full Text] [Related]
6. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.
Derksen PW; de Gorter DJ; Meijer HP; Bende RJ; van Dijk M; Lokhorst HM; Bloem AC; Spaargaren M; Pals ST
Leukemia; 2003 Apr; 17(4):764-74. PubMed ID: 12682635
[TBL] [Abstract][Full Text] [Related]
7. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.
Dai Y; Siemann DW
BMC Cancer; 2012 May; 12():198. PubMed ID: 22639908
[TBL] [Abstract][Full Text] [Related]
8. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.
Scuto A; Krejci P; Popplewell L; Wu J; Wang Y; Kujawski M; Kowolik C; Xin H; Chen L; Wang Y; Kretzner L; Yu H; Wilcox WR; Yen Y; Forman S; Jove R
Leukemia; 2011 Mar; 25(3):538-50. PubMed ID: 21164517
[TBL] [Abstract][Full Text] [Related]
9. Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.
Fedorenko IV; Fang B; Koomen JM; Gibney GT; Smalley KS
Melanoma Res; 2014 Oct; 24(5):448-53. PubMed ID: 24950457
[TBL] [Abstract][Full Text] [Related]
10. Targeting c-met receptor tyrosine kinase by the DNA aptamer SL1 as a potential novel therapeutic option for myeloma.
Zhang Y; Gao H; Zhou W; Sun S; Zeng Y; Zhang H; Liang L; Xiao X; Song J; Ye M; Yang Y; Zhao J; Wang Z; Liu J
J Cell Mol Med; 2018 Dec; 22(12):5978-5990. PubMed ID: 30353654
[TBL] [Abstract][Full Text] [Related]
11. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
[TBL] [Abstract][Full Text] [Related]
12. c-Met signaling promotes IL-6-induced myeloma cell proliferation.
Hov H; Tian E; Holien T; Holt RU; Våtsveen TK; Fagerli UM; Waage A; Børset M; Sundan A
Eur J Haematol; 2009 Apr; 82(4):277-87. PubMed ID: 19187270
[TBL] [Abstract][Full Text] [Related]
13. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.
Dai Y; Siemann DW
Mol Cancer Ther; 2010 Jun; 9(6):1554-61. PubMed ID: 20515943
[TBL] [Abstract][Full Text] [Related]
14. MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?
Gambella M; Palumbo A; Rocci A
Expert Rev Mol Diagn; 2015; 15(7):881-93. PubMed ID: 25967746
[TBL] [Abstract][Full Text] [Related]
15. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.
Cervantes-Gomez F; Chen LS; Orlowski RZ; Gandhi V
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S317-29. PubMed ID: 23988451
[TBL] [Abstract][Full Text] [Related]
16. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.
Crosswell HE; Dasgupta A; Alvarado CS; Watt T; Christensen JG; De P; Durden DL; Findley HW
BMC Cancer; 2009 Nov; 9():411. PubMed ID: 19939254
[TBL] [Abstract][Full Text] [Related]
17. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma.
Derksen PW; Keehnen RM; Evers LM; van Oers MH; Spaargaren M; Pals ST
Blood; 2002 Feb; 99(4):1405-10. PubMed ID: 11830493
[TBL] [Abstract][Full Text] [Related]
18. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.
Moschetta M; Basile A; Ferrucci A; Frassanito MA; Rao L; Ria R; Solimando AG; Giuliani N; Boccarelli A; Fumarola F; Coluccia M; Rossini B; Ruggieri S; Nico B; Maiorano E; Ribatti D; Roccaro AM; Vacca A
Clin Cancer Res; 2013 Aug; 19(16):4371-82. PubMed ID: 23804425
[TBL] [Abstract][Full Text] [Related]
19. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
[TBL] [Abstract][Full Text] [Related]
20. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
